Supernus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson?s disease (PD). The resubmission is now considered filed, with a user fee goal date (PDUFA date) of April 5, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.16 USD | +1.46% | -2.80% | +0.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.76% | 1.58B | |
+10.53% | 9.08B | |
-10.76% | 5.06B | |
+53.60% | 4.85B | |
+7.56% | 3.85B | |
+14.09% | 2.37B | |
-21.42% | 2.36B | |
+25.03% | 2.27B | |
-30.36% | 2.22B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA